phase readout
saveNCT05401786: Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC
ACTIVE_NOT_RECRUITINGupdated 10d ago
community read0 votes
Sponsor: The Netherlands Cancer Institute. Phase: PHASE2. Conditions: Carcinoma, Non-Small-Cell Lung
view source ↗
comments(0)
5-min edit window · permanent after that